More importantly, the remaining p95HER2 constitutively activates the downstream signaling to deliver growth and survival signals to cancer cells, promoting the activity up to 10–100-fold higher than that of the full-length HER2, thus rendering tumor cells refractory to trastuzumab (13, 14). Here, ERBB2 is linked to neoplasm.